title: Influence of topiramate on olanzapine-related adiposity in women: a random, double-blind, placebo-controlled study.
abstract: The aim of this study was to compare the efficacy of topiramate versus a placebo in the treatment of adiposity in women undergoing olanzapine therapy. We also assessed changes health-related quality of life, the patient's actual state of health, and psychologic impairments. The 10-week, random, double-blind, placebo-controlled study included 43 women who had been treated with olanzapine (mean dose 7.8 +/- 3.6 in the topiramate group and 7.2 +/- 3.1 in the placebo group) and had gained weight as a side effect. The subjects were randomly assigned to topiramate (n = 25) or a placebo (n = 18). Primary outcome measures were weight checks and self-reported changes on the scales of the SF-36 Health Survey, Bf-S Scale of Well-Being, and the Adjective Checklist EWL-60-S. Weight loss was observed and was significantly more pronounced in the topiramate-treated group (difference in weight loss between the 2 groups: 5.6 kg, 95% CI = -8.5, -3.0, P < 0.001). In comparison with the placebo group, significant changes on 7 (7/8) scales of SF-36 Health Survey (all P < 0.001), on all 6 scales of the EWL-60-S, and on the Bf-S were observed in the topiramate-treated subjects after 10 weeks. All patients tolerated topiramate well. Topiramate appears to be a safe and effective agent in the treatment of weight gain that occurred during olanzapine treatment. Significantly positive changes in health-related quality of life, the patient's actual state of health, and psychologic impairments were observed.
authors.affiliation: Clinic for Psychosomatic Medicine, Inntalklinik, Simbach/Inn, Germany. m.nickel@inntalklinik.de
authors.forename: Marius K
authors.initials: MK
authors.lastname: Nickel
authors.forename: Cerstin
authors.initials: C
authors.lastname: Nickel
authors.forename: Moritz
authors.initials: M
authors.lastname: Muehlbacher
authors.forename: Peter K
authors.initials: PK
authors.lastname: Leiberich
authors.forename: Patrick
authors.initials: P
authors.lastname: Kaplan
authors.forename: Claas
authors.initials: C
authors.lastname: Lahmann
authors.forename: Karin
authors.initials: K
authors.lastname: Tritt
authors.forename: Jakub
authors.initials: J
authors.lastname: Krawczyk
authors.forename: Christian
authors.initials: C
authors.lastname: Kettler
authors.forename: Christoph
authors.initials: C
authors.lastname: Egger
authors.forename: Wolfhardt K
authors.initials: WK
authors.lastname: Rother
authors.forename: Thomas H
authors.initials: TH
authors.lastname: Loew
mesh_terms: D000273:Adipose Tissue / Q000187:drug effects / Q000378:metabolism; D000328:Adult; D019440:Anti-Obesity Agents / Q000627:therapeutic use; D001569:Benzodiazepines / Q000009:adverse effects / Q000494:pharmacology; D016001:Confidence Intervals; D004311:Double-Blind Method; D005260:Female; D005632:Fructose / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D001523:Mental Disorders / Q000188:drug therapy / Q000523:psychology; D009483:Neuropsychological Tests / Q000706:statistics & numerical data; D000077152:Olanzapine; D018709:Statistics, Nonparametric; D000077236:Topiramate; D015430:Weight Gain / Q000187:drug effects* / Q000502:physiology; D015431:Weight Loss / Q000187:drug effects* / Q000502:physiology
chemical_list: D019440:Anti-Obesity Agents; D000077236:Topiramate; D001569:Benzodiazepines; D005632:Fructose; D000077152:Olanzapine